These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37697390)

  • 1. Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: a case report.
    Iijima H; Sakai A; Ebisumoto K; Yamauchi M; Teramura T; Yamazaki A; Inagi T; Okami K
    J Med Case Rep; 2023 Sep; 17(1):387. PubMed ID: 37697390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
    Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
    J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report.
    Edahiro R; Ishijima M; Kurebe H; Nishida K; Uenami T; Kanazu M; Akazawa Y; Yano Y; Mori M
    Thorac Cancer; 2019 May; 10(5):1276-1279. PubMed ID: 30964601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint-inhibitor pneumonitis: A case report and literature review.
    Nair DR; Trehan R
    Cancer Rep (Hoboken); 2023 Jul; 6(7):e1778. PubMed ID: 36601913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Near complete response to a pembrolizumab-based therapeutic strategy in an abdominal metastatic head and neck squamous cell carcinoma case.
    Wu T; Liang F; Lin P; Li Y; Huang X; Han P
    Hum Vaccin Immunother; 2022 Nov; 18(6):2093075. PubMed ID: 35878084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab Monotherapy
    Matsuo M; Masuda M; Yamauchi M; Taura M; Hashimoto K; Kogo R; Jiromaru R; Hongo T; Manako T; Nakagawa T
    In Vivo; 2023; 37(5):2188-2196. PubMed ID: 37652513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
    Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
    Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
    Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
    Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
    Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
    J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report.
    Tanaka S; Kushimoto M; Nishizawa T; Takubo M; Mitsuke K; Ikeda J; Fujishiro M; Ogawa K; Tsujino I; Suzuki Y; Abe M
    Clin Diabetes Endocrinol; 2020; 6():1. PubMed ID: 31921440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Study of Patients with Recurrent or Metastatic Head and Neck Cancer Treated with Pembrolizumab.
    Iijima H; Sakai A; Ebisumoto K; Murakami T; Maki D; Teramura T; Yamauchi M; Yamazaki A; Inagi T; Okami K
    Tokai J Exp Clin Med; 2022 Sep; 47(3):99-104. PubMed ID: 36073278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
    Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
    J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report.
    Hidaka Y; Arigami T; Osako Y; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
    World J Surg Oncol; 2022 Jun; 20(1):193. PubMed ID: 35689267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.
    Cunha C; Silva E; Vieira AC; Saraiva C; Duarte S
    Endocrinol Diabetes Metab Case Rep; 2022 Feb; 2022():. PubMed ID: 35140188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Recurrent Metastatic Parotid Acinic Cell Carcinoma Responsive to Pembrolizumab.
    Yamashita G; Okamoto I; Shimizu A; Tokashiki K; Okada T; Sato H; Tsukahara K
    In Vivo; 2022; 36(2):1047-1051. PubMed ID: 35241570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.